Trial reportAntimicrobial agents and chemotherapy1997
Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration.
Trial report in Antimicrobial agents and chemotherapy, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 49 citations in OpenAlex.
- Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.Journal of clinical pharmacology · 2020Trial
- Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients.Antimicrobial agents and chemotherapy · 2001Trial
- Evaluation of high dose post-dialytic versus daily beta-lactam dosing in hemodialysis patients using Monte Carlo simulation.International journal of clinical pharmacy · 2026Article
- Removal of common antimicrobial agents by sustained low-efficiency dialysis.Antimicrobial agents and chemotherapy · 2024Article
- Antibiotic dosing recommendations in critically ill patients receiving new innovative kidney replacement therapy.BMC nephrology · 2024Article
- Cefepime Dosing in a Critically Ill Neonate Receiving Continuous Renal Replacement Therapy With the Cardio-Renal Pediatric Dialysis Emergency Machine (CARPEDIEM).The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2023Article
- Cefepime Extraction by Extracorporeal Life Support Circuits.The journal of extra-corporeal technology · 2022Article
- Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.Clinical pharmacokinetics · 2022Article
- Size Matters: The Influence of Patient Size on Antibiotics Exposure Profiles in Critically Ill Patients on Continuous Renal Replacement Therapy.Antibiotics (Basel, Switzerland) · 2021Article
- Myoclonic status epilepticus induced by cefepime overdose requiring haemodialysis.BMJ case reports · 2019Article
- Cefepime Pharmacokinetics in Critically Ill Pediatric Patients Receiving Continuous Renal Replacement Therapy.Antimicrobial agents and chemotherapy · 2019Article
- Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy: a Monte Carlo simulation study.Journal of intensive care · 2018Article
- [Pharmacokinetic and pharmacodynamic aspects in antibiotic treatment].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2014Review
- Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.Annals of intensive care · 2012Article
- Presence and accuracy of drug dosage recommendations for continuous renal replacement therapy in tertiary drug information references.The Canadian journal of hospital pharmacy · 2012Article
- Low cefepime concentrations during high blood and dialysate flow continuous venovenous hemodialysis.Antimicrobial agents and chemotherapy · 2012Article
- Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.Critical care (London, England) · 2011Article
- Cefepime: a reappraisal in an era of increasing antimicrobial resistance.Expert review of anti-infective therapy · 2008Review
- Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.Clinical pharmacokinetics · 2007Review
- Drug dosing during intermittent hemodialysis and continuous renal replacement therapy : special considerations in pediatric patients.Paediatric drugs · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to analyze the pharmacokinetics of cefepime, in six patients with acute renal failure related to septic shock, during continuous venovenous hemodiafiltration (CVVHD) (Hemospal AN 69S hemofilter; Hospal, Lyon, France). Six patients, mean age 65 +/- 4 years (range, 61 to 69), were included and each received 2 g of cefepime by intravenous infusion over a 30-min period every 12 h. Prefilter serum, dialysate outlet (DO), and ultrafiltrate samples were collected 0.47, 0.50, 0.57, 1, 3, 5, 7, and 12 h after the beginning of infusion. The time design of samples was optimized in accordance with the theory of D optimality. The cefepime concentrations were measured by high-performance liquid chromatography. The pharmacokinetics computation was carried out using P-PHARM software. Mean serum concentration peaks were 53 +/- 21.9 mg/liter (range, 13.0 to 68.9) one-half hour after the infusion. The mean elimination half-life was 8.11 +/- 2.22 h (range, 4.76 to 10.84). DO clearance was 66.57 +/- 30.14 ml/min (range, 38.66 to 119.87). The mean volume of distribution was 0.71 +/- 0.37 liters/kg of body weight. CVVHD was effective for cefepime elimination. In these subjects, the elimination half-life and DO clearance were almost constant. The results of this study suggested that a 2-g twice-daily infusion (usual dosage) was required for an effective concentration in this group of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.